Australian scientists unveil promising targeted therapy for rare blood cancer

What happened: Australian scientists identified new immune targets that could enable precision treatment for myelofibrosis, a rare blood cancer.
• Why it matters now: Current therapies mainly ease symptoms and do not cure the disease or eliminate the abnormal cells driving it.
• What changes for people: The research points toward future immunotherapies that selectively remove disease-causing cells instead of broadly suppressing the blood system.
• Who is affected: Patients living with myelofibrosis, oncology researchers, and clinicians treating rare blood disorders.

Australian researchers are reporting a potential breakthrough in the fight against myelofibrosis, a rare cancer that disrupts blood production and severely affects quality of life. Instead of treating symptoms such as fatigue, bone pain and spleen enlargement, scientists have identified a strategy that directly targets the abnormal blood cells fueling the disease.

The work, published in the journal Blood, builds on advances in precision immunology, a field focused on teaching the immune system to recognise and destroy harmful cells while sparing healthy tissue. For patients diagnosed with myelofibrosis, current treatments can help manage discomfort, but no curative therapy exists.

A shift towards targeted treatment

The research team used patient-derived cells to pinpoint two distinct immune targets that effectively eliminate the abnormal cell populations linked to myelofibrosis progression.

According to Prof Daniel Thomas, director of the South Australian Health and Medical Research Institute’s Blood Cancer programme, this represents a major change in strategy. He noted that most available treatments do not discriminate between healthy and diseased cells, whereas a targeted approach could be more effective and less taxing on the body.

Thomas said the findings illustrate that therapies can be designed around what makes disease-driving cells unique, opening the door to more personalised and durable treatments.

Precision immunology shows promise

The study also suggests that myelofibrosis may appear in different biological forms, meaning patients could eventually receive therapies tailored to their specific disease subtype.

Angel Lopez, Head of Human Immunology at SA Pathology, said the future of cancer treatment lies in understanding disease at a molecular and immune level and turning that insight into precise, long-lasting interventions.